Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a repair response ...

In June, the parent company of car brands Citroen and DS - announced an immediate 'stop-drive' order on certain models across ...

Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGN ...

Prior to her appointment at C3 Metals, Dr. Sykora worked as a highly sought after independent consultant with various companies in Canada, USA, Mexico and worldwide. She has held positions with First ...

As Lollapalooza returns to Chicago’s Grant Park this weekend, organizers are once again turning up the volume on ...

Airports across the UK are enforcing different 100ml liquid systems, threatening to cause hold-ups in security lanes as the ...

C3.ai, Inc. AI is capitalizing on the booming demand for enterprise AI. However, the company now faces a critical challenge.

M&A is back is in style again under President Donald Trump. That’s good news for investors in stocks such as C3.ai, Viking ...

Pegcetacoplan inhibits C3 activation by binding to C3 and its activation fragment C3b, thereby reducing C3 glomerular fragment deposition in patients with C3G and primary IC-MPGN.

C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN) are two diseases that have a ...

Founded in 2009 by Thomas Siebel, C3.ai's core purpose has always been to deliver AI solutions to enterprises. Its value ...

The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary ...